Thierry Durroux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7703702/publications.pdf

Version: 2024-02-01

62 papers	3,768 citations	172457 29 h-index	133252 59 g-index
66 all docs	66 docs citations	66 times ranked	3895 citing authors

#	Article	IF	Citations
1	Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nature Methods, 2008, 5, 561-567.	19.0	452
2	Building a new conceptual framework for receptor heteromers. Nature Chemical Biology, 2009, 5, 131-134.	8.0	349
3	Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology, 2010, 6, 587-594.	8.0	306
4	Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis. Molecular Endocrinology, 2003, 17, 677-691.	3.7	296
5	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agentsâ˜†. Progress in Brain Research, 2008, 170, 473-512.	1.4	248
6	Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6733-6738.	7.1	173
7	A Fluorescent Ligand-Binding Alternative Using Tag-liteÂ® Technology. Journal of Biomolecular Screening, 2010, 15, 1248-1259.	2.6	135
8	d-myo-Inositol 1-phosphate as a surrogate of d-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation. Analytical Biochemistry, 2006, 358, 126-135.	2.4	117
9	Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding. Molecular Pharmacology, 2006, 70, 1783-1791.	2.3	107
10	Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus. Journal of the American Society of Nephrology: JASN, 2009, 20, 2190-2203.	6.1	93
11	The oligomeric state sets GABA_Breceptor signalling efficacy. EMBO Journal, 2011, 30, 2336-2349.	7.8	84
12	Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends in Pharmacological Sciences, 2005, 26, 376-384.	8.7	75
13	BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues. Frontiers in Endocrinology, 2012, 3, 92.	3.5	67
14	Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells. ELife, 2017, 6, .	6.0	63
15	Conserved aromatic residues in the transmembrane region VI of the V1avasopressin receptor differentiate agonist vs. antagonist ligand binding. FEBS Journal, 2000, 267, 4253-4263.	0.2	60
16	Toward Efficient Drug Screening by Homogeneous Assays Based on the Development of New Fluorescent Vasopressin and Oxytocin Receptor Ligands. Journal of Medicinal Chemistry, 2007, 50, 4976-4985.	6.4	59
17	A Broad G Protein-Coupled Receptor Internalization Assay that Combines SNAP-Tag Labeling, Diffusion-Enhanced Resonance Energy Transfer, and a Highly Emissive Terbium Cryptate. Frontiers in Endocrinology, 2015, 6, 167.	3.5	56
18	The Metabotropic Glutamate Receptor mGlu7 Activates Phospholipase C, Translocates Munc-13-1 Protein, and Potentiates Glutamate Release at Cerebrocortical Nerve Terminals. Journal of Biological Chemistry, 2010, 285, 17907-17917.	3.4	55

#	Article	IF	Citations
19	Untangling dopamine-adenosine receptor assembly in experimental parkinsonism. DMM Disease Models and Mechanisms, 2015, 8, 57-63.	2.4	55
20	Selective Fluorescent Nonpeptidic Antagonists For Vasopressin V₂GPCR: Application To Ligand Screening and Oligomerization Assays.. Journal of Medicinal Chemistry, 2012, 55, 8588-8602.	6.4	52
21	Direct Identification of Human Oxytocin Receptor-binding Domains Using a Photoactivatable Cyclic Peptide Antagonist. Journal of Biological Chemistry, 2001, 276, 26931-26941.	3.4	51
22	Leukotriene BLT2 Receptor Monomers Activate the Gi2 GTP-binding Protein More Efficiently than Dimers. Journal of Biological Chemistry, 2010, 285, 6337-6347.	3.4	51
23	Synthesis and Characterization of Fluorescent Antagonists and Agonists for Human Oxytocin and Vasopressin V1aReceptors. Journal of Medicinal Chemistry, 2002, 45, 2579-2588.	6.4	43
24	Multicolor timeâ€resolved FÃ¶rster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes. FASEB Journal, 2015, 29, 2235-2246.	0.5	41
25	Time-Resolved FRET Binding Assay to Investigate Hetero-Oligomer Binding Properties: Proof of Concept with Dopamine D₁/D₃ Heterodimer. ACS Chemical Biology, 2015, 10, 466-474.	3.4	39
26	Mapping the Binding Site of Arginine Vasopressin to V_{1a}and V_{1b}Vasopressin Receptors. Molecular Endocrinology, 2007, 21, 512-523.	3.7	33
27	Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nature Communications, 2017, 8, 14253.	12.8	33
28	LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. Journal of Medicinal Chemistry, 2018, 61, 8670-8692.	6.4	33
29	Oligomerization of a G protein-coupled receptor in neurons controlled by its structural dynamics. Scientific Reports, 2018, 8, 10414.	3.3	32
30	Fluorescent Pseudo-Peptide Linear Vasopressin Antagonists:â€‰ Design, Synthesis, and Applications,. Journal of Medicinal Chemistry, 1999, 42, 1312-1319.	6.4	31
31	Context-Dependent Signaling of CXC Chemokine Receptor 4 and Atypical Chemokine Receptor 3. Molecular Pharmacology, 2019, 96, 778-793.	2.3	30
32	The Constitutively Active V2 Receptor Mutants Conferring NSIAD Are Weakly Sensitive to Agonist and Antagonist Regulation. PLoS ONE, 2009, 4, e8383.	2.5	30
33	Pharmacology of Oxytocin and Vasopressin Receptors in the Central and Peripheral Nervous Systema. Annals of the New York Academy of Sciences, 1992, 652, 39-45.	3.8	27
34	Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. Journal of Peptide Science, 2005, 11, 593-608.	1.4	27
35	Familial Nephrogenic Syndrome of Inappropriate Antidiuresis: Dissociation between Aquaporin-2 and Vasopressin Excretion. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E37-E43.	3.6	27
36	Fluorescent ligands to investigate GPCR binding properties and oligomerization. Biochemical Society Transactions, 2013, 41, 148-153.	3.4	27

#	Article	IF	Citations
37	Differential Coupling of the Vasopressin V_{1b} Receptor through Compartmentalization within the Plasma Membrane. Molecular Pharmacology, 2009, 75, 637-647.	2.3	26
38	Original Fluorescent Ligand-Based Assays Open New Perspectives in G-Protein Coupled Receptor Drug Screening. Pharmaceuticals, 2011, 4, 202-214.	3.8	25
39	Differential Involvement of ACKR3 C-Tail in Î²-Arrestin Recruitment, Trafficking and Internalization. Cells, 2021, 10, 618.	4.1	24
40	Time Resolved FRET Strategy with Fluorescent Ligands to Analyze Receptor Interactions in Native Tissues: Application to GPCR Oligomerization. Methods in Molecular Biology, 2011, 746, 373-387.	0.9	22
41	The atypical chemokine receptor 3 interacts with Connexin 43 inhibiting astrocytic gap junctional intercellular communication. Nature Communications, 2020, 11, 4855.	12.8	21
42	Distribution of Signaling Molecules Involved in Vasopressin-induced Ca2+Mobilization in Rat Hepatocyte Multiplets. Journal of Histochemistry and Cytochemistry, 1999, 47, 601-616.	2.5	20
43	Subtlety of the Structureâ"Affinity and Structureâ"Efficacy Relationships around a Nonpeptide Oxytocin Receptor Agonist. Journal of Medicinal Chemistry, 2010, 53, 1546-1562.	6.4	19
44	Selective Nonpeptidic Fluorescent Ligands for Oxytocin Receptor: Design, Synthesis, and Application to Time-Resolved FRET Binding Assay. Journal of Medicinal Chemistry, 2015, 58, 2547-2552.	6.4	19
45	The ligand-bound state of a G protein-coupled receptor stabilizes the interaction of functional cholesterol molecules. Journal of Lipid Research, 2021, 62, 100059.	4.2	17
46	V_{1b} vasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase. Traffic, 2018, 19, 58-82.	2.7	15
47	A near-infrared fluorogenic dimer enables background-free imaging of endogenous GPCRs in living mice. Chemical Science, 2020, 11, 6824-6829.	7.4	15
48	Time-Resolved FRET Strategy to Screen GPCR Ligand Library. Methods in Molecular Biology, 2015, 1272, 23-36.	0.9	15
49	From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G-Protein-Coupled Receptors. Journal of Medicinal Chemistry, 2018, 61, 174-188.	6.4	13
50	Vasoactive intestinal polypeptide and carbachol act synergistically to induce the hydrolysis of inositol containing phospholipids in the rat superior cervical ganglion. Neuroscience Letters, 1987, 75, 211-215.	2.1	12
51	Molecular insights into mechanisms of GPCR hijacking by Staphylococcus aureus. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	12
52	Visualization of Cell Surface Vasopressin V1a Receptors in Rat Hepatocytes with a Fluorescent Linear Antagonist. Journal of Histochemistry and Cytochemistry, 1999, 47, 401-409.	2.5	9
53	Structural insights into recognition of chemokine receptors by Staphylococcus aureus leukotoxins. ELife, 2022, 11, .	6.0	7
54	Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-liteÂ® assays. Neuropharmacology, 2018, 140, 233-245.	4.1	6

#	Article	IF	Citations
55	Design and validation of a homogeneous time-resolved fluorescence cell-based assay targeting the ligand-gated ion channel 5-HT3A. Analytical Biochemistry, 2015, 484, 105-112.	2.4	4
56	Time-Resolved FRET-Based Assays to Characterize G Protein-Coupled Receptor Hetero-oligomer Pharmacology. Methods in Molecular Biology, 2019, 1947, 151-168.	0.9	3
57	Chapter 13 Expression of human vasopressin and oxytocin receptors in Escherichia coli. Progress in Brain Research, 2002, 139, 163-177.	1.4	2
58	Time-resolved FRET approaches to study GPCR complexes. , 0, , 67-89.		2
59	Fluorescent-Based Strategies to Investigate G Protein-Coupled Receptors: Evolution of the Techniques to a Better Understanding. Topics in Medicinal Chemistry, 2017, , 217-252.	0.8	1
60	New Fluorescent Strategies Shine Light on the Evolving Concept of GPCR Oligomerization. Springer Series on Fluorescence, 2012, , 389-415.	0.8	0
61	Fluorescent Ligands and TR-FRET to Study Receptorâ€“Receptor Interactions in the Brain. Neuromethods, 2016, , 99-107.	0.3	0
62	Chemoselective Acylation of Hydrazinopeptides to Access Fluorescent Probes for Time-Resolved FRET Assays on GPCRs. Methods in Molecular Biology, 2019, 1947, 137-147.	0.9	0